# Rapamune Improves Outcomes of Severe H1N1 Pneumonia

> **NCT01620307** · PHASE2 · COMPLETED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 38 (actual)

## Conditions studied

- H1N1 Pneumonia
- Hypoxemia

## Interventions

- **DRUG:** Sirolimus (Rapamune 2mg/day, Pfizer)

## Key facts

- **NCT ID:** NCT01620307
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2012-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01620307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01620307, "Rapamune Improves Outcomes of Severe H1N1 Pneumonia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01620307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*